A Case Report of Subcutaneously Injected Liposomal Cannabidiol Formulation Used as a Compassion Therapy for Pain Management in a Dog

Yael Shilo-Benjamini*, Ahuva Cern, Daniel Zilbersheid, Atara Hod, Eran Lavy, Dinorah Barasch, Yechezkel Barenholz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


A 14-year-old intact mixed breed dog (26 kg) was submitted for a novel cannabidiol (CBD) analgesic treatment. The dog was cachectic and had a testicular neoplasia, hip and elbow osteoarthritis and severe cervical pain. Analgesic treatment included canine osteoarthritic supplement, robencoxib and gabapentin. An additional liposomal CBD injectable formulation at 5 mg/kg was administered subcutaneously between the shoulder blades. The dog was monitored using an activity monitoring collar (PetPace), owner wellbeing questionnaire (Canine Brief Pain Inventory; CBPI), pain interactive visual analog scale (iVAS), blood work and CBD plasma concentrations. A week from the injection and up to 3 weeks afterwards the dog had improved CBPI and iVAS pain scores, and increased collar activity scores. CBD was quantified in plasma for 28 days. Due to disease progression, further difficulty to rise and walk, and relapse to pain after 3 weeks, the owners requested a second liposomal CBD injection, which was performed 4 weeks following the first injection using 3 mg/kg dose. Two days later, the dog was found dead in the yard under direct sun, while environmental temperature was 37°C. Major findings on necropsy revealed evidence of heat stroke and severe cervical disc protrusion with spinal hematoma, none related to liposomal CBD. In conclusion, subcutaneous liposomal CBD produced quantifiable CBD plasma concentrations for 28 days and may be an effective additional treatment as part of multimodal pain management in dogs.

Original languageAmerican English
Article number892306
JournalFrontiers in Veterinary Science
StatePublished - 28 Apr 2022

Bibliographical note

Funding Information:
This work was supported by the Clinical Research Fund of Wu Jieping Medical Foundation (320.6750.19092-11), the Natural Science Foundation of Guangdong Province of China (2020A1515010142), and the Science and Technology Planning Project of Guangzhou (202102010067), the National Natural Science Foundation of China (81902886), and the Fundamental Research Funds for the Central Universities, Sun Yat-sen University (2021qntd34).

Publisher Copyright:
Copyright © 2022 Shilo-Benjamini, Cern, Zilbersheid, Hod, Lavy, Barasch and Barenholz.


  • CBD
  • analgesia
  • cannabidiol
  • dog
  • liposomes
  • pharmacokinetics
  • prolonged release


Dive into the research topics of 'A Case Report of Subcutaneously Injected Liposomal Cannabidiol Formulation Used as a Compassion Therapy for Pain Management in a Dog'. Together they form a unique fingerprint.

Cite this